Engene Holdings released additional preliminary pivotal‑cohort data from its Phase II Legend trial of detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ. The company said the updated results support its plan for a BLA submission next year and reported encouraging efficacy at the amended protocol dose. Investors reacted sharply: Engene shares jumped following the release. The gene‑therapy approach is nonviral and aims to elicit anti‑tumor immunity in a difficult‑to‑treat bladder cancer population; success could accelerate a regulatory filing and set a path for broader commercialization in urothelial oncology.